Tvardi Therapeutics (NASDAQ: TVRD) adds auditor consent in S-1 amendment

Rhea-AI Filing Summary

Tvardi Therapeutics, Inc. filed a Post-Effective Amendment No. 1 to its Form S-1 on April 1, 2026 to include the consent of Deloitte & Touche LLP to its report dated March 31, 2026 relating to financial statements in the Annual Report on Form 10-K for the year ended December 31, 2025. The amendment is an exhibit-only filing under Rule 462(d) and does not change the prospectus or the balance of Part II of the Registration Statement.

Key Figures

Registration Number: 333-287675 Amendment Filing Date: April 1, 2026 Original S-1 Filing Date: May 30, 2025 +3 more

6 metrics

Registration Number 333-287675 Form S-1 Post-Effective Amendment No. 1

Amendment Filing Date April 1, 2026 Post-Effective Amendment No. 1 filing date

Original S-1 Filing Date May 30, 2025 initial Form S-1 filing

Initial Effective Date November 8, 2025 Registration Statement declared effective

Fiscal Year End December 31, 2025 year ended for audited financial statements

Auditor Report Date March 31, 2026 Deloitte & Touche LLP report date

Key Terms

Post-Effective Amendment, Rule 462(d), Prospectus Supplement No. 1, Consent of Independent Registered Public Accounting Firm

4 terms

Post-Effective Amendment regulatory

"This Post-Effective Amendment No. 1 shall become effective upon filing"

A post-effective amendment is an official update to a securities registration document filed after that document has become effective with regulators; it corrects, adds or replaces information about the securities, the company, or an offering. Investors care because it keeps the legal record current and can change what is being sold or the rights attached to shares — like getting a revised product manual after a launch that may affect value or use.

Rule 462(d) regulatory

"filed as an exhibit-only filing solely to file the consent ... filed pursuant to Rule 462(d)"

A Securities and Exchange Commission procedural rule that lets a company quickly register additional shares by re-using an already effective registration filing, rather than submitting a full new application. For investors this matters because it speeds up the issuance of more stock—similar to printing extra tickets from an approved batch—so it can increase supply, dilute existing ownership, and signal a near-term capital raise or financing plan.

Prospectus Supplement No. 1 regulatory

"included in the Prospectus Supplement No. 1 dated April 1, 2026"

Consent of Independent Registered Public Accounting Firm regulatory

"Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm"

Offering Details

base_shelf_indeterminate

Offering

Offering Type base_shelf_indeterminate

As filed with the Securities and Exchange Commission on April 1, 2026

Registration No. 333-287675 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Post-Effective Amendment No. 1

TO

FORM S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

TVARDI THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	2834	75-3175693
(State or other jurisdiction of incorporation or organization)	(Primary Standard Industrial Classification Code Number)	(I.R.S. Employer Identification No.)

3 Sugar Creek Ctr. Blvd.

Suite 525

Sugar Land, TX 77478

(713) 489-8654

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive office)

Imran Alibhai

Chief Executive Officer

3 Sugar Creek Ctr. Blvd.

Suite 525

Sugar Land, TX 77478

(713) 489-8654

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Divakar Gupta

Madison A. Jones

Cooley LLP

55 Hudson Yards

New York, NY 10001

(212) 479-6000

Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this Registration Statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box: x

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. x (333-287675)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated filer	¨		Accelerated filer	¨
Non-accelerated filer	x		Smaller reporting company	x
			Emerging growth company	¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

This Post-Effective Amendment No. 1 shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(d) under the Securities Act of 1933, as amended.

EXPLANATORY NOTE

This Post-Effective Amendment No. 1 (this “Amendment”) to the Registration Statement on Form S-1 of Tvardi Therapeutics, Inc., as amended (File No. 333-287675), initially filed on May 30, 2025 and declared effective by the Securities and Exchange Commission on November 8, 2025 (the “Registration Statement”), is being filed as an exhibit-only filing solely to file the consent of Deloitte & Touche LLP with respect to its report dated March 31, 2026 relating to the financial statements of Tvardi Therapeutics, Inc. contained in its Annual Report on Form 10-K for the year ended December 31, 2025 and included in the Prospectus Supplement No. 1 dated April 1, 2026 filed pursuant to Rule 424(b)(3), filed herewith as Exhibit 23.1 (the “Consent”). Accordingly, this Amendment consists only of the facing page, this explanatory note, Item 16 of Part II of the Registration Statement, the signature pages to the Registration Statement and the Consent. The prospectus and the balance of Part II of the Registration Statement are unchanged hereby and have been omitted.

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 16. Exhibits and Financial Statement Schedules.

(a) Exhibits

Exhibit No.		Description
23.1*		Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.

* Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Houston, State of Texas, on April 1, 2026.

	TVARDI THERAPEUTICS, INC.
	By:	/s/ Imran Alibhai
	Name:	Imran Alibhai
	Title:	Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Signature		Title		Date
/s/ Imran Alibhai		Chief Executive Officer and Director		April 1, 2026
Imran Alibhai		(Principal Executive Officer)
/s/ Dan Conn		Chief Financial Officer		April 1, 2026
Dan Conn		(Principal Financial Officer)
/s/ Stephen O’Brien		Vice President, Finance and Corporate Controller		April 1, 2026
Stephen O’Brien		(Principal Accounting Officer)
*		Chairman of the Board of Directors		April 1, 2026
Sujal Shah
*		Director		April 1, 2026
Wallace Hall
*		Director		April 1, 2026
Michael S. Wyzga
*		Director		April 1, 2026
Cynthia Smith
*		Director		April 1, 2026
Susan Shiff

	By:	/s/ Imran Alibhai
	Name:	Imran Alibhai
	Title:	Attorney-in-fact

FAQ

What did TVRD file in this Post-Effective Amendment No. 1?

Tvardi (TVRD) filed a post-effective amendment to its Form S-1 to furnish the consent of Deloitte & Touche LLP dated March 31, 2026, which relates to financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2025.

Does the amendment change the prospectus or offering terms for TVRD?

No. The amendment is described as an exhibit-only filing and states the prospectus and the balance of Part II of the Registration Statement are unchanged, so the amendment does not alter offering terms included in the previously effective registration.

Why was Deloitte & Touche LLP's consent included in the amendment for TVRD?

The consent was filed to permit inclusion of Deloitte & Touche LLP's report dated March 31, 2026 covering Tvardi's audited financial statements for the year ended December 31, 2025, as part of Prospectus Supplement No. 1 referenced in the amendment.

What filings and dates are referenced in the TVRD amendment?

The amendment references the original Form S-1 filed May 30, 2025, declared effective November 8, 2025, and the post-effective amendment filing date of April 1, 2026, plus the Deloitte report dated March 31, 2026.